valproic acid has been researched along with Cerebral Ischemia in 23 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Previous studies have shown the neuroprotective effects of the valproic acid (2-n-propylpentanoic acid, VPA) against ischemic stroke, but its effects on the ischemia-induced formation of astrogliosis and glial scar are still unknown." | 8.12 | Valproic Acid Inhibits Glial Scar Formation after Ischemic Stroke. ( Gao, X; Guo, Y; He, YY; Zeb, S; Zhang, HL; Zhou, XY; Zhu, YM, 2022) |
| " The antiepileptic drug valproic acid (VPA) was reported to protect cerebral ischemia/reperfusion injury." | 7.91 | Valproic acid attenuates global cerebral ischemia/reperfusion injury in gerbils via anti-pyroptosis pathways. ( Cheng, YY; Guan, L; Jia, LQ; Liu, Y; Min, DY; Song, N; Wang, LJ; Yang, GL; Yang, YJ; Zhan, KX; Zhang, Z; Zhu, S, 2019) |
| "Valproic acid (VA) is an antiepileptic that is also used for the treatment of bipolar disorders." | 5.48 | Neuroprotective effects of valproic acid on brain ischemia are related to its HDAC and GSK3 inhibitions. ( Correia, AO; Costa, RO; da Silva Ribeiro, AE; de Barros Viana, GS; de Siqueira, KP; Dos Santos, GCA; Lima, DGS; Lucetti, DL; Lucetti, ECP; Moura, JA; Neves, KRT; Parente, LLT; Silva, MR, 2018) |
| " Plasma concentrations (pc), interactions between drugs in the ICU context, adverse effects and seizure occurrences were observed and recorded." | 5.37 | Levetiracetam compared to valproic acid: plasma concentration levels, adverse effects and interactions in aneurysmal subarachnoid hemorrhage. ( Bjeljac, M; Keller, E; Mink, S; Muroi, C; Seule, M, 2011) |
| "Previous studies have shown the neuroprotective effects of the valproic acid (2-n-propylpentanoic acid, VPA) against ischemic stroke, but its effects on the ischemia-induced formation of astrogliosis and glial scar are still unknown." | 4.12 | Valproic Acid Inhibits Glial Scar Formation after Ischemic Stroke. ( Gao, X; Guo, Y; He, YY; Zeb, S; Zhang, HL; Zhou, XY; Zhu, YM, 2022) |
| " The antiepileptic drug valproic acid (VPA) was reported to protect cerebral ischemia/reperfusion injury." | 3.91 | Valproic acid attenuates global cerebral ischemia/reperfusion injury in gerbils via anti-pyroptosis pathways. ( Cheng, YY; Guan, L; Jia, LQ; Liu, Y; Min, DY; Song, N; Wang, LJ; Yang, GL; Yang, YJ; Zhan, KX; Zhang, Z; Zhu, S, 2019) |
| "Mice were subjected to middle cerebral artery occlusion (MCAO) model to induce IS injures and then were administrated with VPA." | 1.56 | Valproate improves middle cerebral artery occlusion-induced ischemic cerebral disorders in mice and oxygen-glucose deprivation-induced injuries in microglia by modulating RMRP/PI3K/Akt axis. ( Li, X; Sui, Y, 2020) |
| "Valproic acid (VA) is an antiepileptic that is also used for the treatment of bipolar disorders." | 1.48 | Neuroprotective effects of valproic acid on brain ischemia are related to its HDAC and GSK3 inhibitions. ( Correia, AO; Costa, RO; da Silva Ribeiro, AE; de Barros Viana, GS; de Siqueira, KP; Dos Santos, GCA; Lima, DGS; Lucetti, DL; Lucetti, ECP; Moura, JA; Neves, KRT; Parente, LLT; Silva, MR, 2018) |
| "Hyperglycemia was induced by streptozotocin (STZ) injection 3 days before." | 1.42 | Valproic acid ameliorates ischemic brain injury in hyperglycemic rats with permanent middle cerebral occlusion. ( Abe, A; Aoki, J; Kimura, K; Nishiyama, Y; Nito, C; Okubo, S; Sakamoto, Y; Suda, S; Suzuki, K; Ueda, M, 2015) |
| "Male rats underwent middle cerebral artery occlusion for 60 minutes followed by reperfusion for up to 14 days." | 1.38 | Chronic valproate treatment enhances postischemic angiogenesis and promotes functional recovery in a rat model of ischemic stroke. ( Chibane, F; Chuang, DM; Fessler, EB; Leeds, P; Leng, Y; Munasinghe, J; Tsai, LK; Wang, Z, 2012) |
| " Plasma concentrations (pc), interactions between drugs in the ICU context, adverse effects and seizure occurrences were observed and recorded." | 1.37 | Levetiracetam compared to valproic acid: plasma concentration levels, adverse effects and interactions in aneurysmal subarachnoid hemorrhage. ( Bjeljac, M; Keller, E; Mink, S; Muroi, C; Seule, M, 2011) |
| " In patients with heterozygote (MTHFR) 677C/T polymorphism and under long-term use of certain drugs the determination of Hcy plasma levels may be useful to prevent the development of atherothrombotic disease." | 1.35 | Na VPA-induced acute ischemic stroke in an epileptic patient with methylenetetrahydrofolate reductase gene polymorphism. ( Varoglu, AO, 2009) |
| "Given that there is no effective treatment for stroke, HDAC inhibitors, such as VPA, SB, and TSA, should be evaluated for their potential use for clinical trials in stroke patients." | 1.34 | Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. ( Chen, PS; Chuang, DM; Hong, JS; Kim, HJ; Ren, M; Rowe, M, 2007) |
| "When phenytoin was discontinued, valproate levels increased, and he progressively improved." | 1.30 | Exceptionally long absence status: multifactorial etiology, drug interactions and complications. ( Andermann, F; Bastos, A; D'Agostino, MD; Dubeau, F; Fedi, M, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (8.70) | 18.2507 |
| 2000's | 4 (17.39) | 29.6817 |
| 2010's | 14 (60.87) | 24.3611 |
| 2020's | 3 (13.04) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, X | 1 |
| Zeb, S | 1 |
| He, YY | 1 |
| Guo, Y | 1 |
| Zhu, YM | 1 |
| Zhou, XY | 1 |
| Zhang, HL | 1 |
| Naseh, M | 1 |
| Bayat, M | 1 |
| Akbari, S | 1 |
| Vatanparast, J | 1 |
| Shabani, M | 1 |
| Haghighi, AB | 1 |
| Haghani, M | 1 |
| Li, X | 1 |
| Sui, Y | 1 |
| Brookes, RL | 1 |
| Crichton, S | 1 |
| Wolfe, CDA | 1 |
| Yi, Q | 1 |
| Li, L | 1 |
| Hankey, GJ | 1 |
| Rothwell, PM | 1 |
| Markus, HS | 2 |
| Silva, MR | 1 |
| Correia, AO | 1 |
| Dos Santos, GCA | 1 |
| Parente, LLT | 1 |
| de Siqueira, KP | 1 |
| Lima, DGS | 1 |
| Moura, JA | 1 |
| da Silva Ribeiro, AE | 1 |
| Costa, RO | 1 |
| Lucetti, DL | 1 |
| Lucetti, ECP | 1 |
| Neves, KRT | 1 |
| de Barros Viana, GS | 1 |
| Bolland, MJ | 1 |
| Avenell, A | 1 |
| Gamble, G | 1 |
| Grey, A | 1 |
| Hernández de G, MM | 1 |
| Garay F, JL | 1 |
| Loureiro, NE | 1 |
| Zhu, S | 1 |
| Zhang, Z | 1 |
| Jia, LQ | 1 |
| Zhan, KX | 1 |
| Wang, LJ | 1 |
| Song, N | 1 |
| Liu, Y | 1 |
| Cheng, YY | 1 |
| Yang, YJ | 1 |
| Guan, L | 1 |
| Min, DY | 1 |
| Yang, GL | 1 |
| Suda, S | 3 |
| Katsura, K | 1 |
| Kanamaru, T | 1 |
| Saito, M | 2 |
| Katayama, Y | 2 |
| Belozertsev, IuA | 1 |
| Zapol'skaia, IuA | 1 |
| Belozertsev, FIu | 1 |
| Iuntsev, SV | 1 |
| Katsura, KI | 1 |
| Kamiya, N | 1 |
| Dregan, A | 1 |
| Charlton, J | 1 |
| Wolfe, CD | 1 |
| Gulliford, MC | 1 |
| Merson, TD | 1 |
| Bourne, JA | 1 |
| Ueda, M | 1 |
| Nito, C | 1 |
| Nishiyama, Y | 1 |
| Okubo, S | 1 |
| Abe, A | 1 |
| Aoki, J | 1 |
| Suzuki, K | 1 |
| Sakamoto, Y | 1 |
| Kimura, K | 1 |
| Varoglu, AO | 1 |
| Mink, S | 1 |
| Muroi, C | 1 |
| Seule, M | 1 |
| Bjeljac, M | 1 |
| Keller, E | 1 |
| Das, S | 1 |
| Joardar, S | 1 |
| Chatterjee, R | 1 |
| Guha, G | 1 |
| Hashmi, MA | 1 |
| Wang, Z | 1 |
| Tsai, LK | 1 |
| Munasinghe, J | 1 |
| Leng, Y | 1 |
| Fessler, EB | 1 |
| Chibane, F | 1 |
| Leeds, P | 1 |
| Chuang, DM | 2 |
| Costa, C | 1 |
| Martella, G | 1 |
| Picconi, B | 1 |
| Prosperetti, C | 1 |
| Pisani, A | 1 |
| Di Filippo, M | 1 |
| Pisani, F | 1 |
| Bernardi, G | 1 |
| Calabresi, P | 1 |
| Vorbrodt, AW | 1 |
| Dobrogowska, DH | 1 |
| Kozlowski, PB | 1 |
| Rabe, A | 1 |
| Tarnawski, M | 1 |
| Lee, MH | 1 |
| Kim, HJ | 1 |
| Rowe, M | 1 |
| Ren, M | 1 |
| Hong, JS | 1 |
| Chen, PS | 1 |
| Ibrahim, S | 1 |
| Hyder, SS | 1 |
| D'Agostino, MD | 1 |
| Andermann, F | 1 |
| Dubeau, F | 1 |
| Fedi, M | 1 |
| Bastos, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pilot Study of Seizure Prophylaxis With Levetiracetam in Aneurysmal Subarachnoid Hemorrhage[NCT01935908] | Phase 4 | 0 participants (Actual) | Interventional | 2013-05-31 | Withdrawn (stopped due to no funding) | ||
| A Phase II Multiple Site, Randomized, Placebo-Controlled Trial of Oral Valproic Acid for Autosomal Dominant Retinitis Pigmentosa[NCT01233609] | Phase 2 | 90 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Mean change in best corrected visual acuity as assessed by ETDRS (Early Treatment Diabetic Retinopathy Study) method from baseline to week 52 (NCT01233609)
Timeframe: baseline to week 52
| Intervention | letters read correctly (Mean) |
|---|---|
| Valproic Acid -- Right Eye | -1.4 |
| Valproic Acid--Left Eye | 0.0 |
| Placebo --Right Eye | 0.2 |
| Placebo --Left Eye | 1.3 |
Mean change in visual field area from baseline to 52 weeks. Visual field area is measured with semi-automated kinetic perimetry (SKP) using the Octopus 900 (Haag-Streit) with the I4e target size for each eye and done at least twice to ensure reliable sessions; the visual field area measurements are averaged over the two sessions. Analysis performed with linear mixed model (NCT01233609)
Timeframe: baseline to week 52
| Intervention | Visual field area (degrees squared) (Mean) |
|---|---|
| Placebo--Right Eye | 80.9 |
| Placebo--Left Eye | 115.7 |
| Valproic Acid--Right Eye | 5.3 |
| Valproic Acid--Left Eye | 19.5 |
Mean change in visual field area from baseline to 52 weeks. Visual field area is measured with semi-automated kinetic perimetry (SKP) using the Octopus 900 (Haag-Streit) with the III4e target size for each eye and done at least twice to ensure reliable sessions; the visual field area measurements are averaged over the two sessions. Analysis performed with linear mixed model (NCT01233609)
Timeframe: baseline to week 52
| Intervention | Visual field area (degrees squared) (Mean) |
|---|---|
| Placebo--Right Eye | -122.9 |
| Placebo--Left Eye | -112.0 |
| Valproic Acid--Right Eye | -293.7 |
| Valproic Acid--Left Eye | -237.1 |
Mean change from baseline at week 52 for Full field Hill of Vision (Static perimetry) (NCT01233609)
Timeframe: baseline to week 52
| Intervention | db-steridians (Mean) |
|---|---|
| Placebo--Right Eye | -0.3 |
| Placebo--Left Eye | -1.4 |
| Valproic Acid--Right Eye | -0.2 |
| Valproic Acid--Left Eye | -0.6 |
Mean Change from baseline to week 52 for Static Perimetry Volume --30 Degree Hill of Vision. Full field static perimetry protocol was followed using the Octopus 900 (Haag-Streit) for a single session for each eye. (NCT01233609)
Timeframe: baseline to week 52
| Intervention | db-steridans (Mean) |
|---|---|
| Placebo--Right Eye | -0.3 |
| Placebo--Left Eye | -0.3 |
| Valproic Acid--Right Eye | -0.2 |
| Valproic Acid--Left Eye | -0.2 |
1 review available for valproic acid and Cerebral Ischemia
| Article | Year |
|---|---|
Endogenous neurogenesis following ischaemic brain injury: insights for therapeutic strategies.
Topics: Adult; Animals; Brain Injuries; Brain Ischemia; Histone Deacetylase Inhibitors; Humans; Nerve Regene | 2014 |
1 trial available for valproic acid and Cerebral Ischemia
| Article | Year |
|---|---|
Sodium Valproate, a Histone Deacetylase Inhibitor, Is Associated With Reduced Stroke Risk After Previous Ischemic Stroke or Transient Ischemic Attack.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Brain Ischemia; Disease-Free Survival; Female; Follow-Up S | 2018 |
21 other studies available for valproic acid and Cerebral Ischemia
| Article | Year |
|---|---|
Valproic Acid Inhibits Glial Scar Formation after Ischemic Stroke.
Topics: Animals; Astrocytes; Brain Ischemia; Glial Fibrillary Acidic Protein; Gliosis; Histones; Ischemic St | 2022 |
Neuroprotective effects of sodium valproate on hippocampal cell and volume, and cognitive function in a rat model of focal cerebral ischemia.
Topics: Animals; Brain Ischemia; Cognition; Hippocampus; Infarction, Middle Cerebral Artery; Long-Term Poten | 2022 |
Valproate improves middle cerebral artery occlusion-induced ischemic cerebral disorders in mice and oxygen-glucose deprivation-induced injuries in microglia by modulating RMRP/PI3K/Akt axis.
Topics: Animals; Apoptosis; Brain Ischemia; Enzyme Inhibitors; Glucose; Infarction, Middle Cerebral Artery; | 2020 |
Neuroprotective effects of valproic acid on brain ischemia are related to its HDAC and GSK3 inhibitions.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Brain Ischemia; Cyclooxygenase 2 Inhibitors; Dopamin | 2018 |
Reader response: Expression of Concern: Does compensatory hyperparathyroidism predispose to ischemic stroke? Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy; An alternative to vitamin D supplementation to pre
Topics: Adult; Bone Density; Bone Remodeling; Brain Ischemia; Dietary Supplements; Epilepsy; Humans; Hyperpa | 2018 |
Neuroprotective action of valproic acid accompanied of the modification on the expression of Bcl-2 and activated caspase-3 in the brain of rats submitted to ischemia/reperfusion.
Topics: Animals; Brain Ischemia; Caspase 3; Neuroprotective Agents; Proto-Oncogene Proteins c-bcl-2; Rats; R | 2015 |
Valproic acid attenuates global cerebral ischemia/reperfusion injury in gerbils via anti-pyroptosis pathways.
Topics: Animals; Anticonvulsants; Brain Ischemia; Cell Survival; Cells, Cultured; Dose-Response Relationship | 2019 |
Valproic acid attenuates ischemia-reperfusion injury in the rat brain through inhibition of oxidative stress and inflammation.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Brain Ischemia; Disease Models, Animal; In Situ Nic | 2013 |
[Comparison of neuroprotective effects of anticonvulsant drugs in brain injury therapy].
Topics: Amines; Animals; Animals, Outbred Strains; Anticonvulsants; Brain; Brain Injuries; Brain Ischemia; C | 2012 |
Valproic acid enhances the effect of bone marrow-derived mononuclear cells in a rat ischemic stroke model.
Topics: Animals; Bone Marrow Cells; Bone Marrow Transplantation; Brain Ischemia; Combined Modality Therapy; | 2014 |
Is sodium valproate, an HDAC inhibitor, associated with reduced risk of stroke and myocardial infarction? A nested case-control study.
Topics: Aged; Aged, 80 and over; Bias; Brain Ischemia; Case-Control Studies; Databases, Factual; Electronic | 2014 |
Valproic acid ameliorates ischemic brain injury in hyperglycemic rats with permanent middle cerebral occlusion.
Topics: Animals; Blood Glucose; Brain; Brain Ischemia; Hyperglycemia; Infarction, Middle Cerebral Artery; Ma | 2015 |
Na VPA-induced acute ischemic stroke in an epileptic patient with methylenetetrahydrofolate reductase gene polymorphism.
Topics: 5,10-Methylenetetrahydrofolate Reductase (FADH2); Brain; Brain Ischemia; Epilepsy; Humans; Hyperhomo | 2009 |
Levetiracetam compared to valproic acid: plasma concentration levels, adverse effects and interactions in aneurysmal subarachnoid hemorrhage.
Topics: Administration, Oral; Aged; Aneurysm, Ruptured; Anti-Bacterial Agents; Anticonvulsants; Biological A | 2011 |
Rare magnetic resonance imaging findings in medium-chain acyl-coenzyme A dehydrogenase deficiency.
Topics: Acyl-CoA Dehydrogenase; Anticonvulsants; Basal Ganglia; Brain; Brain Ischemia; Carnitine; Cerebral I | 2011 |
Chronic valproate treatment enhances postischemic angiogenesis and promotes functional recovery in a rat model of ischemic stroke.
Topics: Animals; Anticonvulsants; Blotting, Western; Brain Ischemia; Cerebral Infarction; Hypoxia-Inducible | 2012 |
Multiple mechanisms underlying the neuroprotective effects of antiepileptic drugs against in vitro ischemia.
Topics: Animals; Anticonvulsants; Brain Ischemia; Calcium Signaling; Carbamazepine; Electrophysiology; Excit | 2006 |
Immunogold study of effects of prenatal exposure to lipopolysaccharide and/or valproic acid on the rat blood-brain barrier vessels.
Topics: Albumins; Animals; Blood-Brain Barrier; Brain Ischemia; Cell Membrane; Cerebral Arteries; Child; Dev | 2005 |
Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action.
Topics: Animals; Anti-Inflammatory Agents; Brain; Brain Ischemia; Butyrates; CD11b Antigen; Cerebral Infarct | 2007 |
Moyamoya disease of childhood as a cause of recurrent cerebral ischemic attacks--a case report.
Topics: Anticonvulsants; Brain Ischemia; Carbamazepine; Cerebral Angiography; Child, Preschool; Electroencep | 1996 |
Exceptionally long absence status: multifactorial etiology, drug interactions and complications.
Topics: Aged; Anticonvulsants; Brain Ischemia; Dementia, Vascular; Drug Interactions; Epilepsy, Generalized; | 1999 |